

(51) International Patent Classification:
C07K 14/725 (2006.01)(21) International Application Number:
PCT/US2015/024947(22) International Filing Date:
8 April 2015 (08.04.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/977,751	10 April 2014 (10.04.2014)	US
61/986,479	30 April 2014 (30.04.2014)	US
62/058,973	2 October 2014 (02.10.2014)	US
62/088,363	5 December 2014 (05.12.2014)	US
62/089,730	9 December 2014 (09.12.2014)	US
62/090,845	11 December 2014 (11.12.2014)	US

(71) Applicant: SEATTLE CHILDREN'S HOSPITAL
(DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE) [US/US]; 1900 Ninth Avenue, Seattle, WA 98101 (US).

(72) Inventor: JENSEN, Michael, C.; 1900 Ninth Avenue, Seattle, WA 98101 (US).

(74) Agent: FURMAN, Eric, S.; Knobbe, Martens, Olson & Bear LLP, 2040 Main Street 14th Floor, Irvine, CA 92614 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:


— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

— with sequence listing part of description (Rule 5.2(a))

(54) Title: DRUG RELATED TRANSGENE EXPRESSION

Fig 6A



(57) Abstract: The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8⁺ central memory T cells or combinations of central memory T cells with CD4⁺ T cells that are genetically modified to express a chimeric receptor under the control of an inducible promoter. In some alternatives the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a chimeric antigen receptor comprising a ligand binding domain, a polynucleotide comprising a spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain under the control of a drug inducible promoter. Controlling the expression of the chimeric receptor provides for the ability to turn expression on and off depending on the status of the patient. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.